Enliven Therapeutics Quarterly Cash Flow Statement
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
40.98+0.35 (+0.86%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Enliven Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Enliven Therapeutics generated -$18.5 million of operating cash flow and spent $99,000 on capital expenditures. That left free cash flow of -$18.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Enliven Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -32.48M | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M | -23.16M | -19.95M | -22.74M | -19.37M | -20.77M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 7.00K | 14.00K | 83.00K | 62.00K | 81.00K | 74.00K | 63.00K | 80.00K | 79.00K | 79.00K | 80.00K | 79.00K |
| Stock-Based Compensation | 13.91M | 7.40M | 12.31M | 7.18M | 7.72M | 6.80M | 5.34M | 5.18M | 5.14M | 4.51M | 3.06M | 3.40M |
| Change in Working Capital | -1.50M | -519.00K | 828.00K | -1.02M | 789.00K | 220.00K | 323.00K | -64.00K | -1.60M | 2.15M | -961.00K | -1.59M |
| Operating Cash Flow | -18.53M | -19.29M | -15.84M | -13.28M | -17.06M | -24.13M | -17.20M | -12.19M | -20.43M | -23.36M | -12.48M | -15.89M |
| Capital Expenditures | -99.00K | 0 | 0 | 1.00K | -139.00K | -20.00K | 0 | -22.00K | -2.00K | -20.00K | -14.00K | -16.00K |
| Investing Cash Flow | -441.57M | 42.53M | 12.38M | -4.06M | -183.59M | 1.43M | 727.00K | 14.83M | -33.66M | -17.89M | 38.69M | -35.55M |
| Financing Cash Flow | 463.42M | 10.05M | 623.00K | -368.00K | 218.38M | 234.00K | 39.97M | 1.12M | 1.81M | 90.27M | 90.00K | -425.00K |
| Net Change in Cash | 3.32M | 33.29M | -2.84M | -17.70M | 17.73M | -22.47M | 23.50M | 3.75M | -52.29M | 49.02M | 26.29M | -51.87M |
| Free Cash Flow | -18.63M | -19.29M | -15.84M | -13.28M | -17.20M | -24.15M | -17.20M | -12.21M | -20.44M | -23.38M | -12.50M | -15.91M |
This table shows 12 quarterly periods of Enliven Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ELVN's reporting calendar. What is a cash flow statement?